Underrepresented Populations in Clinical Trials: Considerations

Adequate representation and accessibility in clinical research are critical to ensuring equitable healthcare. The exclusion or underrepresentation of certain population groups compromises the validity and generalizability of clinical trial results.

Inclusive research is necessary to accurately assess the effectiveness of new drugs, therapies, and healthcare technologies across the wider population, addressing disparities in social and health outcomes.

In this white paper, Signant's clinical science leaders examine diversity in clinical trials, uncovering barriers and identifying strategies to improve diversity in trial populations, and ensure high quality evidence generation amongst increasingly diverse patient populations.